GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Return-on-Tangible-Asset

VGI Health Technology (XNEC:VTL) Return-on-Tangible-Asset : 0.00% (As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. VGI Health Technology's annualized Net Income for the quarter that ended in . 20 was A$ Mil. VGI Health Technology's average total tangible assets for the quarter that ended in . 20 was A$ Mil. Therefore, VGI Health Technology's annualized Return-on-Tangible-Asset for the quarter that ended in . 20 was 0.00%.

The historical rank and industry rank for VGI Health Technology's Return-on-Tangible-Asset or its related term are showing as below:

XNEC:VTL's Return-on-Tangible-Asset is not ranked *
in the Biotechnology industry.
Industry Median: -40.12
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

VGI Health Technology Return-on-Tangible-Asset Historical Data

The historical data trend for VGI Health Technology's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology Return-on-Tangible-Asset Chart

VGI Health Technology Annual Data
Trend
Return-on-Tangible-Asset

VGI Health Technology Semi-Annual Data
Return-on-Tangible-Asset

Competitive Comparison of VGI Health Technology's Return-on-Tangible-Asset

For the Biotechnology subindustry, VGI Health Technology's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VGI Health Technology's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's Return-on-Tangible-Asset falls into.



VGI Health Technology Return-on-Tangible-Asset Calculation

VGI Health Technology's annualized Return-on-Tangible-Asset for the fiscal year that ended in . 20 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=/( (+)/ )
=/
= %

VGI Health Technology's annualized Return-on-Tangible-Asset for the quarter that ended in . 20 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is one times the annual (. 20) net income data.


VGI Health Technology  (XNEC:VTL) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


VGI Health Technology Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


VGI Health Technology (XNEC:VTL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003
VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines